Skip to content
Screener

Aeva Technologies AEVA Issuance Of Series A Warrants

Issuance Of Series A Warrants at other companies

NextNav logo
NextNavNN
-$2.25M
NextNav logo
NextNavNN
-$2.25M
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$409.25K
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%
Ispire Technology Inc. logo
Ispire Technology Inc.ISPR
$91.49K
Envoy Medical logo
Envoy MedicalCOCH
$882K+348%

Segments

By segment

See full
Reportable Segment Aggregation Before Other Operating$0

Other financials

Income statement

See full
Revenue$6.3M+85.9%
Gross profit$1.9M+526%
Operating income-$35.1M-15.5%
Net income-$35.0M-0.3%
EPS (diluted)-$0.56+12.5%

Balance sheet

See full
Cash & equivalents$31.2M+47.0%
Total debt$5.3M+87.4%
Total equity-$12.4M-118%
Total assets$147.3M+28.6%

Cash flow

See full
Operating cash flow-$25.8M+16.1%
CapEx$2.2M+385%
Free cash flow-$28.1M+10.2%

Valuation

See full
Market cap$1.73B+128%
Enterprise value$1.7B+131%
P/S82.3×+27.6×

Profitability

See full
Gross margin-18.5%-7.1pp
Operating margin-630.9%-229pp
Net margin-693.9%-240pp
FCF margin-555.5%-181pp

Returns & leverage

See full
Return on equity-258.4%-589pp
Debt / equity0.4×+0.4×
Current ratio4.1×+1.2×

Where this comes from

Reported directly by Aeva Technologies in its filing.

Tagged under the XBRL concept aeva:IssuanceOfSeriesAWarrants.

The source filing: Aeva Technologies’s 10-K, filed March 20, 2026.

Filed
Mar 19, 2026, 9:55 PM EDT
Fiscal year
FY2025
Accession
0001193125-26-116518
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Total operating expenses126,937154,582141,902
Operating loss(127,597)(158,372)(147,788)
Interest income2,7387,7128,925
Fair value at issuance of Series A warrants(6,500)
Change in fair value of warrant liabilities(21,453)(1,486)(182)
Fair value gain on settlement of share subscription liability1,651
Other income (expense), net(459)56(3,788)
Net loss before income taxes(145,120)(152,090)(149,333)

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

FAQ

What is Aeva Technologies's issuance of series a warrants?
Aeva Technologies (AEVA) reported issuance of series a warrants of $0 in Q4 2025.
What is the long-term trend for Aeva Technologies's issuance of series a warrants?
Over 2 years (2023 to 2025), Aeva Technologies's issuance of series a warrants has grown at a -100.0% compound annual growth rate (CAGR), from $6.5M to $0.
What does issuance of series a warrants mean?
Reflects the accounting impact or valuation associated with the issuance of specific equity-linked derivative instruments. This metric indicates the company's use of warrants as a financing tool or incentive mechanism. It is critical for understanding potential future dilution and the company's capital structure strategy.

Ask your AI about Aeva Technologies's issuance of series a warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude